Actively Recruiting
Study of Trastuzumab-rezetecan Treatment in Adults with HER2-Positive or HER2-Low Breast Cancer Observing Effectiveness and Safety in Real-World Settings
Led by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Updated on 2026-01-22
300
Participants Needed
1
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the real-world effectiveness and safety of treatment regimens containing Trastuzumab-rezetecan in patients with HER2-positive and HER2-low breast cancer. This multicenter, observational study plans to enroll 300 patients who are either currently receiving or scheduled to receive this treatment. The study focuses on patients with confirmed HER2 expression and various disease settings, including neoadjuvant, adjuvant, or advancedmetastatic stages. Participants will receive Trastuzumab-rezetecan according to regimens determined by their doctors, with dosages adjusted based on clinical needs. The drug is administered in cycles every 21 days, with doses of 4.8 mgkg for HER2-positive and 6.4 mgkg for HER2-low patients. The study does not restrict the choice of treatment regimens, allowing physicians to individualize therapy. For patients undergoing neoadjuvant therapy, pathological complete response will be assessed after surgery. During the study, patients will have imaging and safety assessments following routine clinical practices, with investigators evaluating results. Safety monitoring includes recording adverse events from consent until 30 days after the last dose. Upon treatment completion or withdrawal, further safety and imaging data will be collected. The study also tracks long-term outcomes such as disease progression and survival over an estimated seven years, involving follow-up visits as outlined in the protocol.
CONDITIONS
Brief Title
Efficacy and Safety of Trastuzumab-rezetecan in HER2-Expressing Breast Cancer
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here